▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Green Cross accelerates long-acting hemophilia drug development

  • PUBLISHED :February 08, 2017 - 17:16
  • UPDATED :February 08, 2017 - 17:16
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] South Korea’s Green Cross is pushing ahead with the development of its long-acting hemophilia A treatment despite a setback last year, sources said on Feb. 8.

The drug maker had to halt clinical trials of the recombinant DNA-based drug for genetic bleeding disorder in the US in October 2016.




The company is currently conducting preclinical studies on its investigational hemophilia treatment MG1121A , aiming to enter first phase clinical programs in the second half of 2018.

“If Green Cross’ once-weekly dosing drug candidate succeeds in commercialization, it will become one of the hemophilia treatments providing the longest dosing interval,” an industry source said.

Hemophilia A is a genetic deficiency in clotting factor 8.

Most of Hemophilia factor 8 treatments require patients to get injections every other day.

SK Chemical’s investigational hemophilia drug Afstyla and Shire’s Adynovate, which won approval from the US Food and Drug Administration last year, should be administered every 3 to 5 days.

MG1121A is the next version of the drug maker’s GreenGene F, for which it suspended clinical trials in the US due to rising costs.

Green Cross said last year it has overhauled the global development strategy for GreenGene F to shift its focus from US and Europe to the fast-growing China market.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS